NCT03384888
Unknown
Not Applicable
Neurostimulation Applied to Fibromyalgia
Federal University of Paraíba1 site in 1 country59 target enrollmentMay 15, 2017
ConditionsFibromyalgia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Fibromyalgia
- Sponsor
- Federal University of Paraíba
- Enrollment
- 59
- Locations
- 1
- Primary Endpoint
- Pain intensity level
- Last Updated
- 7 years ago
Overview
Brief Summary
NeuroFibro is a double-blind, randomized, placebo-controlled clinical trial, using neurostimulation in women with fibromyalgia.
Investigators
Géssika Araújo de Melo
Eliane Araújo de Oliveira
Federal University of Paraíba
Eligibility Criteria
Inclusion Criteria
- •(1) diagnosis of fibromyalgia, according to the American College of Rheumatology criteria;
- •(2) been diagnosed for at least three months;
- •(3) be female;
- •(4) be in the age group between 25 and 60 years of age; and
- •(5) sign the consent form.
Exclusion Criteria
- •(1) cognitive deficit, evaluated through the Mini Mental State Examination (MMSE);
- •(2) illiterate;
- •(3) people with metallic implants located on the head, cochlear implants and cardiac pacemaker;
- •(4) history of convulsion;
- •(5) severe depression, measured by score greater than 36 on Beck Depression Inventory; and
- •(6) be pregnant.
Outcomes
Primary Outcomes
Pain intensity level
Time Frame: Baseline (week 1); Endpoint (week 2 or 3 depending on the arm)
Changes in pain level, assessed by the Visual Analog Scale, ranges from 0 - 10, with 10 being the highest level of pain.
Secondary Outcomes
- Quality of life level(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
- Anxiety level(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
- Depression level(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
- Cognitive function(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
- Cortical electrical activity(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
- Health assessment level(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
- Sleep quality(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
- Resilience(Baseline (week 1); Endpoint (week 2 or 3 depending on the arm))
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With FibromyalgiaFibromyalgiaNCT01173055University of Michigan22
Completed
Not Applicable
Brain Stimulation for Neurological PatientsAlzheimer DiseaseNCT03770182Storz Medical AG60
Completed
Phase 2
Efficacy and Safety of NYX-2925 in Subjects With FibromyalgiaFibromyalgiaNCT04147858Aptinyx310
Completed
Phase 2
Fibromyalgia Study In AdultsFibromyalgia Syndrome, PrimaryNCT00256893GlaxoSmithKline164
Completed
Phase 3
NeuroAiD II™ (MLC901) in Mild Traumatic Brain InjuryTraumatic Brain InjuryNCT04861688Moleac Pte Ltd.182